ALGS
Aligos Therapeutics (ALGS)
$
94About Aligos Therapeutics (ALGS)
Aligos Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which engages in the provision of therapeutics for chronic liver diseases and viral infections. The firm is focused on the discovery and development of targeted antiviral therapies for chronic hepatitis B (CHB) and coronaviruses, as well as leveraging its expertise in liver diseases to create targeted therapeutics for nonalcoholic steatohepatitis (NASH). The company was founded by Lucinda Quan and Lawrence M. Blatt on February 5, 2018 and is headquartered in South San Francisco, CA.
Details
Daily high
$6.45
Daily low
$5.75
Price at open
$5.79
52 Week High
$46.80
52 Week Low
$3.76
Market cap
34.7M
Dividend yield
0.00%
Volume
371,988
Avg. volume
139,369
P/E ratio
-.33
Aligos Therapeutics News
Details
Daily high
$6.45
Daily low
$5.75
Price at open
$5.79
52 Week High
$46.80
52 Week Low
$3.76
Market cap
34.7M
Dividend yield
0.00%
Volume
371,988
Avg. volume
139,369
P/E ratio
-.33